srch

Mar 07, 2022 · Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives.

Mar 07, 2022 · Targovax TRVX is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax's focus is to activate the patient's immune system to fight...

Targovax's pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer.

Targovax AS - Product Pipeline Review - 2015 Summary Global Markets Direct s, Targovax AS - Product Pipeline Review - 2015, provides an overview of the...

Mar 07, 2022 · The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer ... -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of ...

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

The company's pipeline includes a several of product candidates aimed at different cancer types such as melanoma, mesothelioma and peritoneal cancers.

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing ... of a rich pipeline of innovative future immunotherapy product candidates.

Pipeline · Pipeline · Our pipeline · Development Program · Melanoma · Mesothelioma · Collaboration Trials · New viruses · Partnering · Investors & Media.

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

TARGOVAX´S THREE-PILLAR R&D PIPELINE STRATEGY. 67. Novel ONCOS-102 combinations o Maximize clinical impact of ONCOS-102 through novel clinical.

Feb 28, 2022 · OSLO, Norway, Feb. 28, 2022 /PRNewswire/ -- Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that...

Oslo, Norway, 12 January 2022 – Targovax ASA (OSE: TRVX) a clinical stage ... Targovax's pipeline aims at different cancer indications, ...

07.03.2022 · Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and thereby bring benefit to cancer patients with few available treatment alternatives.

Expanded the pipeline programs into circular RNA delivery. Appointed Dr. Erik Digman Wiklund as CEO, previous Targovax CBO and CFO and.

May 02, 2018 · Targovax's development pipeline has three novel therapeutic candidates in clinical development covering six indications. Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner.

Feb 28, 2022 · OSLO, Norway, Feb. 28, 2022 /PRNewswire/ -- Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO), effective as of 7 March 2022.

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

Targovax's pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer.

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors.

07.03.2022 · The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technologyThe agreement may be ...

28.02.2022 · OSLO, Norway, Feb. 28, 2022 /PRNewswire/ -- Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that...

28.02.2022 · OSLO, Norway, Feb. 28, 2022 /PRNewswire/ -- Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO), effective as of 7 March 2022.